Nasdaq GlobeNewswire

World Conference on Lung Cancer Sunday Press Conference: Introducing New Awards and Global Guidelines

Del

YOKOHAMA, Japan, Oct. 15, 2017 (GLOBE NEWSWIRE) -- The first press briefing at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) highlighted new awards and innovations that encourage and support the treatment of lung cancer and other thoracic malignancies; these include the recognition of outstanding care teams, introduction of new guidelines for nurses and fostering the next generation of researchers.

The press conference began with a welcome message from Conference Co-Presidents Dr. Hisao Asamura and Dr. Keunchil Park, who have worked tirelessly to make this year's conference in Yokohama a major success.

The first Cancer Care Team Award recognizes exceptional patient care
The IASLC Foundation is awarding its first-ever Cancer Care Team Award to multidisciplinary cancer care teams across the globe who go above and beyond to provide the highest-quality patient care. The award was proposed by Dr. Matthew Holman and his wife, Marilyn, a lung cancer survivor. Jill Feldman, a lung cancer survivor and advocate from the United States, introduced the award by telling her story and sharing why this award is particularly meaningful to her.

"My team at Rush University has always been patient-centered and is so deserving of this award, along with the other awardees today," said Jill Feldman. "Amazing things are possible when teams across disciplines work together to put the patient first. I am grateful to the IASLC Foundation for introducing an award that encourages this kind of extraordinary teamwork."

Teams at the following institutions were recognized with the award:

  • Guangdong Lung Cancer Institute (China)
  • Neotorax - Oncologia D'or (Brazil)
  • Instytut Gruzlicy i Chorób Pluc w Warszawie (Poland); Klinika Chorób Wewnetrznych, Pneumonologii i Alergologii, Samodzielny Publiczny szpital Kliniczny w Warszawie (Poland); Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie w Warszawie (Poland)
  • Johns Hopkins Hospital - Sidney Kimmel Cancer Center (USA)
  • Rush University Medical Center (USA)

New guidelines for nurses provide best practices for immunotherapy treatment
At last year's WCLC in Vienna, the IASLC Nursing and Allied Health Committee identified the need for educational support for those caring for lung cancer patients receiving immunotherapy. During today's press conference, Kim Rohan of the United States and Anne Fraser of New Zealand unveiled the resulting guidelines for immunotherapy. The guidelines are an invaluable resource to nurses and cover the life-threatening adverse effects patients may experience during immunotherapy treatment including gastrointestinal, dermatologic, endocrine, ocular, hepatic, neurological and pulmonary toxicities.

"These guidelines are unique in that they are the result of international collaboration," said Anne Fraser. "As immunotherapy treatment continues to be utilized more frequently, the guidelines will be essential to helping nurses understand and mitigate the potential side effects."

IASLC Mentorship Award participants speak to the value of mentorship
The IASLC International Mentorship Program is a professional development and education program for early-career thoracic malignancy-focused physicians and researchers from economically developing countries. Thirteen mentees were selected for the 2017 program, representing specialties from medical oncology to pulmonology and hailing from Argentina, China, India, Indonesia, Malaysia, Pakistan, Saudi Arabia, Serbia and Thailand. Some of the world's leading figures in lung cancer will provide mentorship and guidance during the WCLC, as well as host the mentees at their home institutions for a week.

A number of mentors shared their experiences with the program and underscored the value of mentorship, including Fiona Blackhall of the United Kingdom, Ross Camidge of the United States, Nir Peled of Israel and Mary O'Brien of the United Kingdom.

For Prof. Blackhall, the benefits of mentorship include the ability to inspire the next generation of oncologists and cancer researchers, serve as a female role model in medicine and highlight areas of unmet need in lung cancer research. Prof. Peled found that there were mutual benefits of working with his mentee, as he has been able to enlarge his team network. Dr. Camidge, who is based in Denver, discussed his long-distance collaboration with his mentee, Harry Ren of China. They jointly diagnosed a patient who then traveled to Denver for a clinical trial, demonstrating the value of global collaboration.

Mary O'Brien also spoke to why mentorship is so critical for young professionals in the field. "Medicine is a profession traditionally taught as an apprenticeship, learning from and watching senior doctors. Medicine has changed and much is not taught through books and other sources of information. We need to remember the power of human contact. A strong mentorship scheme will bring the best out of young doctors, talents that are both obvious and hidden," said Dr. O'Brien.

Livestreams of the daily press conferences are available here.

About the WCLC
The World Conference on Lung Cancer (WCLC) is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting over 6,000 researchers, physicians and specialists from more than 100 countries. The goal is to disseminate the latest scientific achievements; increase awareness, collaboration and understanding of lung cancer; and to help participants implement the latest developments across the globe. Organized under the theme of "Synergy to Conquer Lung Cancer," the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit wclc2017.iaslc.org.

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Contacts:             
Hillary Wasserman 
Senior Associate
HWasserman@GroupGordon.com
+1 732-778-1896

Becky Bunn, MSc
Public Relations Manager
Becky.Bunn@IASLC.org
+1 720-254-9509



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IASLC via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Anima Biotech Named U.S. Deal of the Year Winner at Lifestars™ Life Science Awards20.11.2018 16:17Pressemelding

Award recognizes the transformative potential of Anima’s $1B+ collaboration with Lilly BERNARDSVILLE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of drugs that specifically control protein translation, has been named winner of the “U.S. Deal of the Year” award at the 2018 Lifestars AwardsTM. “We are delighted to receive this award, which recognizes the power and potential of our Translation Control Therapeutics platform,” said Yochi Slonim, co-founder and chief executive officer of Anima Biotech. “Our deal with Lilly further validates our approach and our partnering strategy of creating exclusive collaborations around our partners’ chosen targets.” “Lifestars presented a fantastic opportunity to bring together a deserved audience and highlight the advances being made in our industry. It’s a testament to Anima Biotech’s efforts that this year’s judging faculty commended them in this manner,” said Neil Darkes, Co-CEO, LSX Ltd. And Lifestars. The int

Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics20.11.2018 15:00Pressemelding

US and EU patents for TissueCypher® cover methods for detecting risk of progression to esophageal cancer in Barrett’s esophagus patients PITTSBURGH, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Cernostics, developer of next-generation cancer diagnostics and prognostics, announced that it has received a U.S. Patent and a European Notice to Grant for the company’s TissueCypher® Barrett’s Esophagus Assay, adding protection to previously awarded foundational, platform patents granted in 2014. Earlier this month, Cernostics received notification from the European Patent Office that claims will be issued for its patent entitled “Systems and Compositions for Diagnosing Barrett’s Esophagus and Methods for Using the Same.” This notice comes on the heels of a recent issuance of a corresponding U.S. patent (U.S. Patent No. 10,018,631). Cernostics’ recent patent claims relate to the company’s clinical test for predicting disease progression in patients with BE and assessment of the likelihood that BE may fur

Gratomic Announces Over-Subscription Non-Brokered Private Placement20.11.2018 14:00Pressemelding

TORONTO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. (“GRAT” or the “Company”) (TSX-V: GRAT) (FRANKFURT:CB81, WKN:A143MR) is pleased to announce that the offering of a non-brokered private placement announced on November 16, 2018 has been over-subscribed and the Company will be offering up to 20,000,000 working capital units (the “WC Unit”) for up to $2,000,000 (the “Offering”). Each WC Unit is priced at $0.10 and consists of one (1) common share and one (1) common share purchase warrant (“WC Warrant”). Each WC Warrant entitles the holder to purchase one (1) common share (a “WC Warrant Share”) at a price of $0.20 per WC Warrant Share until the earlier of: (i) three (3) years following the Closing of the Offering; and (ii) in the event that the closing price of the Common Shares on the TSX Venture Exchange is at least $0.30 for ten (10) consecutive trading days, and the 10th trading day (the “Final Trading Day”) is at least four (4) months from the Closing Date, the date which is th

Ondot Systems Named One of North America’s Fastest Growing Companies in Deloitte’s 2018 Technology Fast 500™20.11.2018 14:00Pressemelding

Ranked Fastest Growing FinTech Company in Silicon Valley with 224 percent revenue growth and over four thousand Financial Institutions now offering its white label service Santa Clara, California, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Ondot Systems, the leading provider of Digital Card Services and Customer Empowerment Solutions, today announced that it was named by Deloitte’s Technology Fast 500TM as the fastest growing Silicon Valley FinTech company, and one of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. A recent report “Accelerating Digital Transformation in Banking” published by Deloitte on results of a survey of 17,100 consumers across 17 countries concluded that leading technology companies have become the gold standard for digital engagement, thus driving a stronger emotional connection for consumers with these brands over their primary banks. If banks want to keep up, they must engineer their digital exper

Patton Delivers IPv6 Services at the Network Edge20.11.2018 13:15Pressemelding

Implementing enhanced IPv6 in SmartNode VoIP CPE, Patton supports simplified network architectures and lowers operation and maintenance costs for service providers and enterprises. SmartNode VoIP… More than Just Talk! GAITHERSBURG, Md., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Patton Electronics—doing business as a bricks-and-mortar manufacturer since 1984—has enhanced IPv6 in its SmartNode CPE, the company announced today. Global expansion of the Internet, proliferation of IP endpoint devices, and the burgeoning Internet of Things (IoT) means we will soon run out of IPv4 addresses. The IPv6 standard expands available IP addresses octillion times, or at least 17 billion . Everyone has known that for a long time and the hype has been going on for years. Service providers made plans, and some partially implemented IPv6 in their networks. Carriers like Telefonica and T-MOBILE—and enterprises such as Microsoft—have started the changeover. Many large enterprises also planned on it, but have spotty

SoftServe Achieves ISO 13485 Standard for Medical Device Quality Management Systems20.11.2018 13:00Pressemelding

International standard ensures customer and regulatory requirements are consistently met for the lifecycle of medical device products AUSTIN, Texas, Nov. 20, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it has achieved the ISO 13485:2016 standard – an internationally recognized standard that defines quality management system requirements for medical device manufacturers as set by the International Organization for Standardization (ISO). SoftServe implemented and established a quality management system compliant with the requirements of ISO 13485:2016. This activity was verified by third-party audits by Loyd’s Register, an accredited certification company. One critical advantage of the certification is it cultivates a preventative approach to assure software medical device quality versus a reactive approach of inspection and rejection during production. “With software as a medical device and software in a medical device continuing to

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom